A class-action lawsuit claims Merck overcharged for a less potent mumps vaccine, violating the Sherman Act. The District Court denied Merck's summary judgment, acknowledging ethical issues but ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off ...

NOBIVAC NXT FeLV is the first FeLV vaccine leveraging Merck's RNA-particle platform, similar to the technology behind their recent rabies and canine flu vaccines. Ian Tarpey, vice president of ...

The same technology was used for NOBIVAC NXT Rabies that launched ... Merck Animal Health. "Merck Animal Health and our NOBIVAC brand have a rich history in vaccine innovation, and we’re ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Merck’s (NYSE:MRK) human papillomavirus (HPV) vaccine Gardasil 9 has met key efficacy goals in a pivotal late-stage trial involving Japanese males ages 16 to 26 years. The Phase 3 V503-064 trial ...

(MRK), Tuesday announced the expansion of Nobivac NXT vaccine platform ... for Nobivac NXT Rabies and Nobivac NXT Canine Flu H3N2, both launched in June 2024. Currently, Merck's stock is trading ...

FDA approval of Merck’s new pneumococcal vaccine, Capvaxive, tees up a new challenge to one of Pfizer’s most important products.

Merck Underscores Continued Commitment to Fighting Infectious Diseases with More than 40 Data Presentations Across Vaccines, Antibacterials and Antivirals, Including Respiratory Syncytial Virus ...